BACKGROUND: Transcranial Doppler ultrasound (TCD) has been demonstrated to be a powerful predictor of stroke risk due to sickle cell disease (SCD) in pediatric populations. Little is known about how this healthcare innovation has disseminated into preventive care for SCD. The objective of this study was to determine TCD screening rates and modifiable patient barriers in children with SCD. PROCEDURE: We retrospectively assessed the screening of 207 children with SCD at the Texas Children's Sickle Cell Center over a 3-year period (2004-2006). Demographics, adherence to comprehensive care visits, severity of disease, and distance from the sickle cell center were obtained from computerized medical record databases. Screenings cancelled or missed by patients were extracted from a computerized order entry system. RESULTS: The average yearly screening rate for eligible patients was 45%. The average yearly cancellation rate by patients was 20%. Patient with private insurance were three times more likely to be compliant with ordered screenings than patients with Medicaid (P = 0.0077). Patients adherent to hematology comprehensive care visits more likely underwent ordered screenings than those who were not (P = 0.0386). When given at least one opportunity per year, providers, on average, ordered TCD screening 74% of the time when it was indicated. CONCLUSIONS: Despite evidence that routine screening to assess stroke risk is vital to the preventive care of SCD, implementation of this healthcare technology may be slow to disseminate due to patient and provider related factors. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: Transcranial Doppler ultrasound (TCD) has been demonstrated to be a powerful predictor of stroke risk due to sickle cell disease (SCD) in pediatric populations. Little is known about how this healthcare innovation has disseminated into preventive care for SCD. The objective of this study was to determine TCD screening rates and modifiable patient barriers in children with SCD. PROCEDURE: We retrospectively assessed the screening of 207 children with SCD at the Texas Children's Sickle Cell Center over a 3-year period (2004-2006). Demographics, adherence to comprehensive care visits, severity of disease, and distance from the sickle cell center were obtained from computerized medical record databases. Screenings cancelled or missed by patients were extracted from a computerized order entry system. RESULTS: The average yearly screening rate for eligible patients was 45%. The average yearly cancellation rate by patients was 20%. Patient with private insurance were three times more likely to be compliant with ordered screenings than patients with Medicaid (P = 0.0077). Patients adherent to hematology comprehensive care visits more likely underwent ordered screenings than those who were not (P = 0.0386). When given at least one opportunity per year, providers, on average, ordered TCD screening 74% of the time when it was indicated. CONCLUSIONS: Despite evidence that routine screening to assess stroke risk is vital to the preventive care of SCD, implementation of this healthcare technology may be slow to disseminate due to patient and provider related factors. (c) 2008 Wiley-Liss, Inc.
Authors: Robert M Cronin; Manshu Yang; Jane S Hankins; Jeannie Byrd; Brandi M Pernell; Adetola Kassim; Patricia Adams-Graves; Alexis A Thompson; Karen Kalinyak; Michael DeBaun; Marsha Treadwell Journal: Hematology Date: 2020-12 Impact factor: 2.269
Authors: Cindy E Neunert; Robert W Gibson; Peter A Lane; Pragya Verma-Bhatnagar; Vaughn Barry; Mei Zhou; Angela Snyder Journal: Am J Prev Med Date: 2016-07 Impact factor: 5.043
Authors: Evelyn M Stevens; Chavis A Patterson; Yimei B Li; Kim Smith-Whitley; Lamia P Barakat Journal: Am J Prev Med Date: 2016-07 Impact factor: 5.043
Authors: David G Bundy; John Muschelli; Gwendolyn D Clemens; John J Strouse; Richard E Thompson; James F Casella; Marlene R Miller Journal: J Pediatr Hematol Oncol Date: 2016-05 Impact factor: 1.289
Authors: Robert J Adams; Dan T Lackland; Lynette Brown; David Brown; Jenifer Voeks; Heather J Fullerton; Julie Kanter; Janet L Kwiatkowski Journal: Am J Hematol Date: 2016-10-25 Impact factor: 10.047
Authors: Raffaella Colombatti; Giorgio Meneghetti; Mario Ermani; Marta Pierobon; Laura Sainati Journal: Ital J Pediatr Date: 2009-06-22 Impact factor: 2.638